+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a master protocol study called IIBD to evaluate the safety and effectiveness of new treatments for adults with moderately to severely active ulcerative colitis or Crohns disease. This phase 2, randomized, controlled study includes multiple individual sub-studies that share key design features. Participants are assigned to the appropriate sub-study before being randomized to a treatment group, with the overall study lasting at least 62 weeks. The study treatments include mirikizumab given intravenously IV during the first study period. Responders then receive mirikizumab subcutaneously SC in the second period. Another group will receive oral LY4395089 combined with IV mirikizumab initially, then responders stop LY4395089 and continue with mirikizumab SC. These two treatment approaches are being assessed in parallel groups. Participants will undergo screening to confirm diagnosis and disease activity, followed by regular study visits during the treatment periods. Researchers will monitor laboratory test results and evaluate response to treatment using measures such as the modified Mayo score for ulcerative colitis and the Crohns disease activity index. The primary outcome includes tracking the number of participants assigned to each treatment group up to day 42. The study runs through March 2028 with ongoing safety and efficacy assessments.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called LY4395089, a farnesoid X receptor FXR agonist, when given together with mirikizumab compared to mirikizumab alone in adults with moderately to severely active Crohns disease. This Phase 2 study is part of the IIBD master protocol and is expected to last about 62 weeks. The goal is to better understand how this combination treatment works for this condition. Participants will be assigned to one of two groups one receiving only mirikizumab and the other receiving both LY4395089 orally and mirikizumab intravenously during the first study period. Responders will then stop LY4395089 and receive mirikizumab subcutaneously in the second study period. Mirikizumab is given first via IV and later by a subcutaneous injection. The study compares these treatment approaches to assess differences in response. During the study, participants will undergo assessments including endoscopic evaluation to measure response up to week 12, clinical remission checks, and fecal calprotectin tests to monitor inflammation levels. Researchers will track safety and efficacy throughout the approximately 62-week study duration. Participants will have regular visits for treatment administration and monitoring, with the main focus on the percentage of participants achieving endoscopic response by week 12.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
E

Actively Recruiting

Researchers are evaluating MK-8690 in adults with moderately to severely active ulcerative colitis to determine if it can help achieve clinical remission by Week 12. This phase 2a study compares MK-8690 to a placebo and aims to see if MK-8690 is more effective based on the Modified Mayo Score. Participants will receive subcutaneous injections of MK-8690 or placebo for 12 weeks. Those who do not respond to the initial treatment will receive MK-8690 for another 12 weeks. Responders from either treatment period will have the option to continue MK-8690 for up to approximately 42 additional weeks. During the study, participants will be monitored for clinical remission, response, endoscopic improvement, and mucosal healing using scores like the Modified Mayo Score at Week 12. Safety will be assessed by tracking adverse events throughout the trial, which lasts up to about 12 months. The study involves randomization and triple masking to ensure unbiased results.

Age: 18Years - 75YearsAll GendersPhase 2
39 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
I

Actively Recruiting

The trial focuses on moderate and late preterm infants born between 32 and 36 weeks gestation who are admitted to Level 2 and 3 Neonatal Intensive Care Units NICUs across Alberta. Researchers aim to find out if applying collaborative quality improvement methods and standardized care bundles can reduce the length of hospital stays and help babies get home faster. This stepped-wedge cluster randomized trial includes 12 NICUs randomized to adopt the intervention at different times, allowing comparison against current standard care. The intervention involves multiple collaborative quality improvement strategies building dedicated QI teams in each NICU, providing standardized QI education, implementing two care bundles focused on respiratory and nutritional support, mentoring by experienced QI members, and facilitating collaborative networking with regular virtual and in-person meetings. Participating NICUs will transition from current practices to this intervention in phases over three years. During the control period, NICUs continue their usual care and any ongoing QI activities without the new intervention strategies. Participants progress will be monitored from birth until discharge or death, with assessments continuing up to six months after their due date. Researchers will track hospital stay length, healthcare costs, respiratory support duration, feeding milestones, growth measurements, rehospitalizations, mortality, and staff perceptions of QI implementation. Data will be collected through clinical records and surveys. The study spans from May 2023 to August 2027, aiming to improve care quality and outcomes for these preterm infants.

Age: 32Weeks - 36WeeksAll GendersPhase Not Applicable
12 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the use of contingency management alongside cognitive behavioural therapy CBT as a treatment for people with gambling disorder living in rural and remote areas. This randomized clinical trial aims to see if adding contingency management improves attendance and retention in counselling sessions compared to CBT alone. The study uses internet video-conferencing to make counselling accessible for participants who might otherwise have difficulty receiving care. Participants are randomly assigned to receive either CBT alone or CBT combined with contingency management CM. The CM group earns points for attending sessions and showing evidence of gambling abstinence, which they can redeem for goods from online stores. Both groups will attend online counselling sessions three times per week for 12 weeks. The full participation period lasts 14 weeks, including one week of assessments before treatment and one week after. During the study, participants complete assessments before and after treatment to evaluate clinical, psychological, and behavioral aspects, including substance use. These assessments take about 30 to 45 minutes. The principal investigator conducts brief progress check-ups during treatment. A smaller group of participants, counsellors, and community members will share their experiences in interviews lasting 30 to 60 minutes. Researchers focus on measuring gambling abstinence, session attendance, and study retention throughout the 12-week treatment.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are conducting a global, multicenter, and long-term observational study called the Pompe Disease Registry to track the natural history and outcomes of Pompe disease in patients, whether they are receiving treatment or not. This registry aims to improve understanding of the diseases variability, progression, and identification to better guide therapeutic interventions and patient care. The registry collects data from patients diagnosed with Pompe disease to characterize the disease population and evaluate the long-term effectiveness of alglucosidase alfa. It serves multiple purposes, including fulfilling regulatory commitments, supporting product development and reimbursement, and enabling other research and non-research uses. Participants provide information over many years, up to 30 years, helping researchers understand the diseases manifestations and progression. The registry gathers data that assists the medical community in developing monitoring recommendations and producing patient outcome reports to optimize care. Participation involves ongoing data collection but does not include experimental treatments or interventions.

All AgesAll Genders
282 locations
P

Actively Recruiting

Researchers are studying prostate cancer treatment by evaluating how tumors inside the prostate respond to a reduced number of radiotherapy sessions. This study focuses on comparing traditional 5-session radiotherapy to a new approach where treatment is given in only 2 sessions, with doses adjusted based on tumor response seen in MRI scans. This Phase 2 trial aims to determine the safety and effectiveness of this personalized radiation method. Participants are divided into two groups. The first group receives 5 radiotherapy sessions to the prostate, possibly including pelvic lymph nodes, with an MRI scan at the midpoint to assess tumor response. The second group receives a single initial radiation dose targeting the prostate and any identified tumor nodules, followed by a second MRI after 3 weeks. A second radiation dose is then given based on the MRI results, allowing for adjustment of treatment to the tumors response. During the study, participants undergo MRI scans, imaging assessments, and clinical evaluations at baseline, during treatment, and at multiple follow-up points up to two years. Researchers measure tumor response, erectile function, prostate-specific antigen levels, and other prostate cancer-related health outcomes. Safety and side effects are carefully monitored throughout the treatment and follow-up periods to assess the impact of the personalized radiotherapy approach.

Age: 18Years +MALEPhase 2
1 location